

## Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial: Erratum

In the article beginning on page e0890 in the April 2023 compendium, the following error was found.

On page 10, column 1, paragraph 2, the following sentence:

LyVP has been demonstrated to have twice the affinity for V1 receptors (primarily located in vascular smooth muscle) and six times greater affinity for V2 receptors (primarily located in the distal nephron) than vasopressin (9, 21, 22).

Should be changed to:

LyVP has been demonstrated to have 2–3 times lower affinity for V1 receptors (primarily located in vascular smooth muscle) and ~12 times lower affinity for V2 receptors (primarily located in the distal nephron) than vasopressin (9, 21, 22).

## REFERENCE

---

Karvellas CJ, Subramanian R, Olson JC, et al: Role of terlipressin in patients with hepatorenal syndrome-acute kidney injury admitted to the ICU: A substudy of the CONFIRM trial. *Crit Care Explor* 2023; 5:e0890

DOI: 10.1097/CCE.0000000000001080